Summary NM23 is a putative metastasis-suppressor gene for some human cancers. Here we have studied NM23 expression during melanoma progression using Northern blotting and immunocytochemistry. There was no significant difference in the average amounts of NM23 mRNA between cell lines derived from metastatic and primary melanomas. The level of NM23 mRNA was also determined for three pairs of poorly metastatic parental (P) and their highly metastatic variant (M) cell lines; the ratios for M/P were 1.2, 0.98 and 0.80. Next we used immunocytochemistry to study NM23 protein in normal skin, benign naevi and primary and metastatic melanomas. Melanocytes in all normal skin and benign samples were positive for NM23; however most primary melanomas (7/11) were not stained by the antibody. All metastatic melanoma samples (5/5) were positively stained. Findings were similar with an antiserum reactive with both forms of NM23 (H1 and H2), and with an antibody specific for NM23-H 1. No relationship was apparent between NM23 immunoreactivity in primary tumours and their aggressiveness or prognosis. Hence, in contrast to the situation described for murine melanoma, the amount of NM23 mRNA or protein in human melanoma did not correlate inversely with metastasis.
Successful metastasis is a complex series of biological events Dorudi and Hart, 1993) . Acquisition of metastatic capacity by a cell appears to involve both positive and negative changes in gene expression . Hence subtractive and differential cDNA hybridisation methods provide approaches for the isolation of relevant genes (Hart and Easty, 1991) , starting from closely related tumour cell lines selected for differing metastatic behaviour in experimental assays (Fidler and Radinsky, 1990) . Thus a panel of subclones from mouse melanoma K1735 was used to isolate the metastasissuppressor gene nm23 on the basis of a lower level of expression in highly metastatic compared with poorly metastatic clones (Steeg et al., 1988) . The human homologues of the gene are NM23-H1 and NM23-H2, both mapping to chromosome 17q21 (Chang et al., 1994) . They encode the monomers of nucleoside diphosphate kinases (NDPK)-A and -B respectively. Both are homohexamers, except that hybrid forms containing both NDPK-A and -B subunits have been found in erythrocytes (Gilles et al., 1991) .
It is not known whether these mixed forms occur elsewhere. These proteins may also have other functions, notably a DNA-binding activity (Postel et al., 1993) or a protein serine kinase activity Bertheau et al., 1994) . Suppressor activity was further indicated when transfection of murine nm23 into the highly metastatic melanoma subline K1735 TK resulted in significantly reduced metastasis (Leone et al., 1991) .
More recent studies however have not shown a universal pattern of deficient expression of this gene in metastatic tumours. In other mouse melanoma sublines (Parker and Sherbet, 1992) , further clones derived from line K1735, and human tumour cell clones (Radinsky et al., 1992) , no correlation was detected between nm23 transcription levels and metastatic potential. In studies of various human cancers, an inverse correlation of NM23 mRNA or protein expression with metastatic potential has been described in some cases (Bevilacqua et al., 1989; Hennessy et al., 1991; Hirayama et al., 1991; Fl0renes et al., 1992) , but not others (Sastre-Garau et al., 1992; Radinsky et al., 1992; Higashiyama et al., 1992; Sawan et al., 1994) . Moreover, groups who also examined related normal or benign tissues generally reported that expression of NM23 was lower there than typically seen in malignant lesions (e.g. Lacombe et Hirayama et al., 1991; Hailat et al., 1991; Sawan et al., 1994) . The amount of NM23-Hl mRNA in human metastatic melanoma has been studied by two groups (Fl0renes et al., 1992; Xerri et al., 1994) . Both groups reported generally decreased amounts in more aggressive tumours. Fl0renes and colleagues found that metastases appearing soon after diagnosis of the primary tumour had significantly lower levels of NM23 mRNA than metastases that developed after a longer time. Similarly Xerri et al. (1994) when studying patients with melanoma metastasis confined to regional lymph nodes, found significantly longer survival associated with higher levels of NM23 mRNA in the resected nodes. Conversely Fl0renes et al. (1992) , also found lower levels of NM23 mRNA in benign naevi than in metastases, and speculated that NM23-H1 might act as a suppressor of differentiation in melanocytes, as previously suggested for NM23-H2 in lymphocytes (Okabe-Kado et al., 1992) .
Data from Northern blotting using fresh tumour samples will be influenced by any non-neoplastic cells present (including stromal cells and any inflammatory infiltrate), and also will not provide information regarding tumour heterogeneity. To circumvent these problems we have used:
(1) Northern blotting to study 30 cell lines derived from lesions at various stages of melanoma progression; and (2) immunocytochemistry to study human biopsy material. To ensure that data from cell lines were relevant to metastasis we included three pairs of poorly metastatic parental lines and their highly metastatic variant lines. These human cell lines were previously selected and assayed in nude (thymusdeficient) mice (Ormerod et al., 1986 , Herlyn et al., 1990 , and so resemble the murine melanoma cell lines used initially to isolate nm23 (Steeg et al., 1988) .
The amount of NM23 mRNA (by Northern blotting) has been shown to correlate well with protein expression assessed with an anti-NM23 polyclonal antiserum (Sawan et al., 1994 Representative sections (more than half of the total stained previously with the rabbit antibody and additional new blocks) were also stained with a monoclonal antibody to NM23-H1 that does not cross-react with NM23-H2 (nm23-H1/NM301, Santa Cruz Biotechnology). This was diluted 1:50; detection was with an alkaline phosphatase-conjugated rabbit anti-mouse antiserum (Sigma). Antibody incubation and substrate development were as described above.
Standardisation of immunostaining was made possible by inclusion of normal skin in each experiment. Normal skin consistently contained intensely stained sweat and sebaceous glands and weakly stained or unstained epidermis. Normal skin present at the edges of some test sections gave a further control. Sections were graded using a five point scale as previously described (Sawan et al., 1994) . Absence of staining (0) and weak, equivocal staining (+ /-) were classed as negative, while unequivocal weak (+), moderate (+ +) and intense (+ + +) staining were classed as positive.
Culture of melanocytes and melanomas Normal melanocytes and melanomas were cultured as previously described (Easty et al., 1993) . Biological details of most of the lines used here are tabulated in Easty et al., (1995a,b) . Melanoma cell line (Ormerod et al., 1986) . Similarly A375M is a highly metastatic variant line that was derived from the poorly metastatic parental line A375P in the same way. Thus, three pairs of poorly metastatic parental lines and their highly metastatic variants were examined for NM23 expression. The metastatic behaviour of these variants is stable (Ormerod et al., 1986; Herlyn et al., 1990) ; nevertheless the earliest available passage was used for Northern blotting to minimise clonal drift. All melanoma lines were cultured in Dulbecco's modification of Eagle's medium with 5% fetal calf serum, except for WM1650, a line derived from the radial growth phase of a primary melanoma, which was grown in melanocyte medium (Easty et al., 1993) .
Northern blotting analysis Total RNA was isolated and poly (A)' RNA selected by oligo(dT)-cellulose chromatography as described previously (Easty et al., 1993) . Aliquots (10 pg) of poly(A)-enriched RNA were separated by electrophoresis in agarose gels containing formaldehyde and transferred to nitrocellulose membranes. Prehybridisation (4 h) and hybridisation (18 h) were at 42°C in 5 x SSPE, 5 x Denhardt's solution, 50% w/v formamide, 500 pg ml-' salmon sperm DNA and 10% w/v sodium dodecyl sulphate (SDS). The final wash was in 0.5 x SSPE and 0.1% SDS at 65°C. After washing, filters were autoradiographed for up to 1 h. The probe used was an NM23-HJ sequence, a gift from Dr P Steeg (Steeg et al., 1988) . This would be expected to detect NM23-H2 as well, because of the high homology of the two coding sequences. Probes were labelled by random hexamer priming (Feinberg and Vogelstein, 1984) 
Results

Northern blotting
By Northern analysis a 0.8 kb NM23 transcript was detected in all cell lines studied. This mRNA was highly expressed (easily detected by autoradiography in 30 min), although with an 11-fold range of level (Figure 1 ). The levels of NM23 mRNA in cell lines derived from primary and metastatic melanomas were compared (Figure 2 and Table I Three pairs of poorly metastatic cell lines (P) and highly metastatic variants (M) were examined by Northern blotting (Table I ). The ratios M/P for NM23 mRNA were: 1.20 (DX3LT5.1/DX3), 0.98 (A375M/A375P), and 0.80 (451LU/ WM164). Thus there was no obvious relationship between the level of NM23 transcription in these cell lines and their metastatic behaviour in nude mice. Nor could we detect any strong relationship with cell differentiation. The normal melanocytes and two of the melanoma lines used, WM1650 and SKMEL23, were morphologically differentiated, pigmented and non-tumorigenic in nude mice; however there was an . . . . R . Table I for details. (Figure 3 ). This provided an internal control for NM23 reaction in pathological material that contained adjacent normal skin. Inflammatory and stromal cells in lesions (including lymphocytes, macrophages and fibroblasts) were generally unstained.
Most pathological specimens showed heterogeneous staining of cells forming the lesion. Staining was generally cytoplasmic. There was intense staining of melanocytes in junctional nests of compound naevi (+ + +) with some more weakly stained cells (+ to + +) in the dermis ( Figure 3) ; there was some indication of reduced staining with increasing depth in the dermis (from + + + to + +). Similar patterns were observed in compound naevi with melanocytic dysplasia (not shown). In contrast, primary melanomas (both RGP and VGP) were more weakly stained, areas within a lesion varying from 0 to + or occasionally + +. Lesions were scored as positive if they contained any clearly stained malignant cells. Some primary melanomas (7/11) were unstained (0) or gave at best an equivocal reaction (+/-), and so were classed as negative (Figure 4) . Melanoma metastases also tended to react heterogeneously for NM23. However, in all samples from metastases the majority of melanoma cells were moderately or highly stained and lesions were thus scored as + + or + + + ( Figure 5 ). Nuclear staining was observed in some cases.
Similar patterns of staining were obtained when the anti-NM23-H1 monoclonal antibody was used, except that in some compound naevi immunostaining was only moderate (+ to + +), and occasionally restricted to one part of the naevus in contrast with the situation with the rabbit anti-NM23 antibody which bound to all parts. The reaction in melanoma metastases was intense (+ + +) and the pattern of staining closely resembled that found previously with the rabbit antiserum.
There was no apparent relationship between NM23 immunoreactivity and prognosis. Positive NM23 staining was seen in 3/6 primary melanomas from which metastasis was subsequently detected (median time from resection of the primary tumour, 7 months, range 1-24 months), and in 1/5 Figure 4 Lack of immunohistochemical staining for NM23 in a VGP primary melanoma using a rabbit polyclonal antibody. There was no clear staining in tumour cells. Brown melanin can be seen in the cytoplasm of some melanoma cells. 
Discussion
Some previous studies have concluded that the expression of NM23 in certain human cancers correlates inversely with the incidence of metastases (Hennessy et al., 1989; Hirayama et al., 1991; Fl0renes et al., 1992; . The approach has been often to determine the level of NM23 expression in primary tumours in comparison with the incidence of metastasis (or prognosis) in the patients. Alternatively, Fl0renes et al. (1992) and Xerri et al. (1994) determined the level of NM23 mRNA in melanoma metastases and compared this with the aggressiveness of the primary tumour. Here we examined primary melanomas and related the expression of NM23 to the same measure of tumour aggressiveness (the interval between diagnosis of primary and secondary tumours) as used in the earlier study (Fl0renes et al., 1992) . The NM23-HI and -H2 transcripts are 88% homologous, and Northern analyses that use full-length NM23 probes will detect mRNA for both genes (Leone et al., 1993) . Such studies include the present work and two previous reports on NM23 in human melanoma (Fl0renes et al., 1992; Xerri et al., 1994) . These genes are not always similarly regulated and the Hl gene product may be a better marker for metastasis in at least some tumours (Tokunaga et al., 1993) . Nevertheless, both previous studies of human melanoma found reduced amounts of total NM23 mRNA in more aggressive tumours. For the present study we used a similar probe, and a rabbit polyclonal antibody that cross-reacts with both gene products. For comparison we also included an antibody specific for NM23-H1.
We did observe generally decreased NM23 protein levels in primary melanomas as compared with melanocytes in naevi. More than half the primary melanomas were unstained (Table II) . However, no relationship was apparent between the amount of NM23 in the primary melanomas and the subsequent incidence of metastasis for this small group of patients. Immunostaining for NM23 in these lesions was generally heterogeneous. Tumour heterogeneity for metastatic propensity has been well documented (e.g. Fidler and Radinsky, 1990) , and it is possible that metastases arose selectively from cells lacking NM23 within these lesions even when the lesion overall was classified as positive. However, if so, one might expect that melanoma metastases would have at least as low a level of NM23 expression as primary tumours, and that primary tumours expressing no NM23 would have the poorest prognosis. Neither was the case: we found high levels of NM23 protein in all metastatic melanomas studied.
With the polyclonal antibody there was intense immunohistochemical staining for NM23 in benign naevi. This apparently contrasts with the finding of low NM23-HI mRNA levels in naevi by Florenes et al. (1992) . Naevi are generally small, thin, discontinuous lesions and biopsies are likely to contain epidermis and dermis, which express little NM23 and might dilute NM23 mRNA from naevus cells. Another possible source of discrepancy might be high expression of NM23-H2/NDPK-B in naevi. This might be detected to a lesser extent by the NM23-HI gene probe than by the rabbit antibody. Consistent with this, the NM23-Hlspecific antibody reacted only weakly with some naevi. However, other naevi were strongly stained, indicating high expression of NM23-HI protein in at least some naevi. Moreover, from results with this antibody, NM23-HI was highly expressed in all melanoma metastases tested.
NM23 mRNA levels in cultured melanoma cells ranged from lower than those in cultured normal melanocytes to several fold higher; there was no significant difference between the distributions of amounts in metastatic and primary melanoma cell lines. Using immunohistochemistry we found more NM23 protein in metastases than in primary melanomas. This tendency seems surprising given that it was in melanoma that a metastasis-suppressor activity of nm23 was first demonstrated. Recalling the often high expression of NM23-HJ mRNA in metastatic cell lines, it is possible that an abnormal form of NM23-HI is being overexpressed. It was recently reported that point mutations of NM23-HI can be coupled with amplification of the gene in neuroblastoma (Chang et al., 1994) . This is reminiscent of findings with the p53 tumour-suppressor gene: either (1) inactivation and silencing of the normal p53 gene; or (2) overexpression of a mutated form of the gene can be oncogenic (Levine, 1993) . We are currently examining this further by sequencing NM23-HJ genes from metastatic melanomas. Our results raise the possibility that, while in primary human melanoma expression of the NM23-HJ gene tends to be repressed, overexpression of an altered gene becomes a more common mechanism during progression and metastasis. 
